Selective HLA Haplotype Loss in Npm1-Positive Acute Myeloid Leukaemia: A Model of Immunological Escape.

doi:10.1111/tan.70058

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Selective HLA Haplotype Loss in Npm1-Positive Acute Myeloid Leukaemia: A Model of Immunological Escape.

HLA - 1 Feb 2025

Rombolà Giovanni, Crocchiolo Roberto, Falco Michela, Iozzi Sara, Marseglia Giuseppina, Amoriello Roberta, Ballerini Clara, Donnini Irene, Nozzoli Chiara, Papola Franco

Abstract excerpt

The exposure of cancer neoantigens to the patient's immune system by the HLA system sustains immune surveillance and shapes tumour clonal evolution. In acute myeloid leukaemia (AML), the mutation of Nucleophosmin 1 (NPM1) at exon 12 represents a driver mutation, raising a set of highly immunogenic peptides. Whereas the phenomenon of HLA loss is a mechanism of immune escape broadly described in allogeneic...

Read the complete abstract on PubMed

Topics

Humans
Middle Aged
Exons
Haplotypes
HLA Antigens
Killer Cells, Natural

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Leukemia, Myeloid, Acute

Mutation

Nuclear Proteins

Nucleophosmin

Receptors, KIR

Tumor Escape

Female

Source

Open in PubMed

Identifiers

PMID: 39933756
DOI: 10.1111/tan.70058

Genes

NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective HLA Haplotype Loss in Npm1-Positive Acute Myeloid Leukaemia: A Model of Immunological Escape.PMID 39933756Read ↗

Protective effects for HLA-B*40:01 and C*03:04 in NPM1-mutated AML: result of a large HLA association study.Semantic proximity Read ↗

Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia.Semantic proximity Read ↗

Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.Semantic proximity Read ↗

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?Semantic proximity Read ↗

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosminSemantic proximity Read ↗

Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosminSemantic proximity Read ↗

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)Semantic proximity Read ↗

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AMLSemantic proximity Read ↗

Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes.Semantic proximity Read ↗

Immunotherapeutic Potential of Mutated NPM1 for the Treatment of AMLSemantic proximity Read ↗

Rapid parallel acquisition of somatic mutations after NPM1 in acute myeloid leukaemia evolution.Semantic proximity Read ↗

Probable HLA-mediated immunoediting of JAK2 V617F-driven oncogenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.